World's Best Scientists 2026 revealed!
Lesley Seymour

Lesley Seymour

D-Index & Metrics

Medicine

D-Index
83
Citations
43637
World Ranking
15356
National Ranking
638

Lesley Seymour publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Lesley Seymour sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 349 publications — 27th percentile

27% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Lesley Seymour D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Lesley Seymour sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 83 D-Index — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Lesley Seymour is affiliated with Queen's University in Canada and has a significant body of research in the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their scholarly contributions focus prominently on oncology and pulmonary and respiratory medicine, with substantial work in cancer research and molecular biology.

The primary areas of study covered by Seymour include:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Molecular Biology
  • Economics and Econometrics

The main topics addressed across their publications encompass:

  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Lung Cancer Treatments and Mutations
  • Cancer Treatment and Pharmacology
  • Health Systems, Economic Evaluations, Quality of Life
  • Statistical Methods in Clinical Trials
  • Occupational and environmental lung diseases

Lesley Seymour's recent scientific papers include:

  • Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies, 2022, Nature Communications
  • Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022, 2022, Annals of Oncology
  • Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial, 2023, The Lancet
  • Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance, 2023, BMJ
  • IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial., 2023, Journal of Clinical Oncology

Frequent co-authors collaborating with Seymour include:

  • Dongsheng Tu
  • Scott A. Laurie
  • John Hilton
  • Moira Rushton
  • Wei Tu

The most common publication venues where Seymour's work appears are:

  • Journal of Clinical Oncology
  • Cancer Research
  • Clinical Cancer Research
  • Annals of Oncology
  • Journal of Thoracic Oncology

Best Publications

  • Erlotinib in previously treated non-small-cell lung cancer.

    Frances A. Shepherd;José Rodrigues Pereira;Tudor Ciuleanu;Eng Huat Tan

  • Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

    Jean Pierre Pignon;Hélène Tribodet;Giorgio V. Scagliotti;Jean Yves Douillard

  • iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

    Lesley Seymour;Jan Bogaerts;Andrea Perrone;Robert Ford

  • Erlotinib in lung cancer - molecular and clinical predictors of outcome.

    Ming Sound Tsao;Akira Sakurada;Jean Claude Cutz;Jean Claude Cutz;Chang Qi Zhu;Chang Qi Zhu

  • Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer

    Timothy Winton;Robert Livingston;David H Johnson;James Rigas

  • RECIST 1.1—Update and clarification: From the RECIST committee

    Lawrence H. Schwartz;Lawrence H. Schwartz;Saskia Litiere;Elisabeth G. E. de Vries;Robert Ford

  • Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study.

    Kerby Shedden;Jeremy M.G. Taylor;Steven A. Enkemann;Ming Sound Tsao

  • Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21

    Chang Qi Zhu;Gilda Da Cunha Santos;Keyue Ding;Akira Sakurada

  • Clinical Predictive Value of the in Vitro Cell Line, Human Xenograft, and Mouse Allograft Preclinical Cancer Models

    Theodora Voskoglou-Nomikos;Joseph L. Pater;Lesley Seymour

  • Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

    Sarah Burdett;S. Burdett;R. Stephens;L. Stewart

  • High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial.

    W R Bezwoda;L Seymour;R D Dansey

  • Comparison of Gemcitabine Versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

    Malcolm J. Moore;J. Hamm;J. Dancey;P. D. Eisenberg

  • Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non–Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10

    Charles A. Butts;Keyue Ding;Lesley Seymour;Philip Twumasi-Ankrah

  • Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non–Small-Cell Lung Cancer

    Chang Qi Zhu;Keyue Ding;Dan Strumpf;Barbara A. Weir

  • Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21

    Andrea Bezjak;Dongsheng Tu;Lesley Seymour;Gary Clark

  • ERCC1 Isoform Expression and DNA Repair in Non-Small-Cell Lung Cancer

    Luc Friboulet;Ken André Olaussen;Ken André Olaussen;Jean Pierre Pignon;Frances A. Shepherd

  • Prognostic and Predictive Importance of p53 and RAS for Adjuvant Chemotherapy in Non–Small-Cell Lung Cancer

    Ming Sound Tsao;Sarit Aviel-Ronen;Keyue Ding;Davina Lau

  • Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer

    Srikala S Sridhar;Lesley Seymour;Frances A Shepherd

  • A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial

    F. A. Shepherd;J. Pereira;T. E. Ciuleanu;E. H. Tan

  • Age and Comorbidity As Independent Prognostic Factors in the Treatment of Non–Small-Cell Lung Cancer: A Review of National Cancer Institute of Canada Clinical Trials Group Trials

    Timothy R. Asmis;Keyue Ding;Lesley Seymour;Frances A. Shepherd

Frequent Co-Authors

Frances A. Shepherd
Frances A. Shepherd Princess Margaret Cancer Centre
Dongsheng Tu
Dongsheng Tu Queen's University
Ming-Sound Tsao
Ming-Sound Tsao Princess Margaret Cancer Centre
Natasha B. Leighl
Natasha B. Leighl Princess Margaret Cancer Centre
Karen A. Gelmon
Karen A. Gelmon University of British Columbia
Jean-Yves Douillard
Jean-Yves Douillard European Society for Medical Oncology
Kim N. Chi
Kim N. Chi BC Cancer Agency
Jean-Charles Soria
Jean-Charles Soria Amgen (United States)
Elizabeth A. Eisenhauer
Elizabeth A. Eisenhauer Queen's University
Elisabeth Brambilla
Elisabeth Brambilla Grenoble Alpes University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The pathway to a career in medicine is diverse and expanding, with many related degrees and online options available. Students who want to pursue administrative or leadership positions in healthcare may consider cahme accredited online healthcare administration programs. These programs provide rigorous training in management skills and health policy, all through accredited and flexible online coursework.

For nurses seeking career advancement, online bridge programs are increasingly popular. Options like online rn to bsn programs without clinical requirements offer a streamlined path for registered nurses to earn a BSN, with no on-site clinical hours required.

If you’re interested in advanced practice nursing, there are accelerated and accessible options available. You can explore the fastest dnp online program to complete your Doctor of Nursing Practice in less time. Alternatively, you may consider one of the easiest dnp programs if you’re looking for flexible admission criteria or a more manageable workload.

These online degree pathways open doors to fulfilling roles in the healthcare field, whether in clinical practice, leadership, or administration.

Best Scientists Citing Lesley Seymour

Trending Scientists

Recently Published Articles